Piper Sandler analyst Edward Tenthoff maintained a Buy rating on Karyopharm Therapeutics (KPTI – Research Report) today and set a price target ...

Piper Sandler lowered the firm’s price target on Karyopharm (KPTI) to split-adjusted $15 from $75 and keeps an Overweight rating on the shares ...

In this article, we are going to take a look at where Karyopharm Therapeutics Inc. (NASDAQ:KPTI) stands against the other one-dollar stocks. The upward trend in the stock market has resumed ...

Karyopharm Therapeutics (KPTI) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.36 per share a year ago.

Stay updated on market trends for KPTI. Down -12.14% in 4 Weeks, Here's Why Karyopharm Therapeutics Looks Ripe for a Turnaround Karyopharm Therapeutics (NASDAQ: KPTI) has been beaten down lately ...

Good morning. My name is Joelle, and I will be your conference operator today. At this time, I would like to welcome everyone to the Karyopharm Therapeutics fourth quarter and full year 2024 ...

Michael Mano, the SVP of $KPTI, sold 2,793 shares of the company on 03-04-2025 for an estimated $17,567. We received data on the trade from a recent SEC filing. This ...

Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Free Report) crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $11.04 and traded as low as ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...